{"id":14644,"date":"2023-05-25T22:28:31","date_gmt":"2023-05-26T02:28:31","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/?post_type=private_project&#038;p=14644"},"modified":"2025-08-18T14:10:57","modified_gmt":"2025-08-18T18:10:57","slug":"costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii","status":"publish","type":"private_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/","title":{"rendered":"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma)"},"content":{"rendered":"\n<p><strong>Client<\/strong>: HOPE Research Centre, Sunnybrook Research Institute<br><br><strong>Project ID:<\/strong> P2022-114\/2023 0970 348 000<\/p>\n\n\n\n<p><strong>Research Question\/Objectives:<\/strong> Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL), primarily affecting B-lymphocytes. It is often diagnosed at an advanced stage and has a poor prognosis since it responds poorly to treatment. Even if initial treatment is successful, almost all patients eventually relapse. Disease severity significantly increases in a relapsed setting where sequential therapy is less effective, leading to poorer outcomes and higher mortality rates. In addition to disease stage, MCL can be graded based on whether it is indolent (low-grade) or aggressive (high-grade), and standard management of indolent MCL includes active surveillance (e.g., routine examination and diagnostic imaging).<\/p>\n\n\n<p><strong>Objectives:<\/strong><\/p>\n<p>Primary Objective:<\/p>\n<ul>\n<li>To describe MCL treatment patterns by line of therapy and categorical type of therapy received per line<\/li>\n<\/ul>\n<p>Secondary Objectives:<\/p>\n<ul>\n<li>To describe annual incidence of MCL<\/li>\n<li>To describe clinical and demographic characteristics of patients diagnosed with MCL<\/li>\n<li>To describe overall survival (OS) of patients with MCL, from diagnosis to death, overall and by categorical treatment sequence<\/li>\n<li>To describe OS of patients with MCL, from time of treatment initiation to death, by line of therapy and categorical type of therapy per line<\/li>\n<li>To describe direct healthcare resource utilization (HCRU) and costs following diagnosis with MCL, overall, and by line of therapy and categorical type of therapy per line<\/li>\n<\/ul>\n<p>Exploratory Objectives:<\/p>\n<ul>\n<li>To describe palliative care usage, costs and outcomes among patients diagnosed with MCL<\/li>\n<\/ul>\n\n\n<p><strong>Status:<\/strong> Completed<\/p>\n\n\n\n<p><strong>Results: <\/strong>May 2026<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Client: HOPE Research Centre, Sunnybrook Research Institute Project ID: P2022-114\/2023 0970 348 000 Research Question\/Objectives: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL), primarily affecting B-lymphocytes. It is often diagnosed at an advanced stage and has a poor prognosis since it responds poorly to treatment. Even if initial treatment [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[105],"response_type":[],"class_list":["post-14644","private_project","type-private_project","status-publish","hentry","project_status-completed"],"acf":{"project_id":"P2022-114\/2023 0970 348 000","project_id_year":2022,"project_id_index":37,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma) | ICES<\/title>\n<meta name=\"description\" content=\"Client: HOPE Research Centre, Sunnybrook Research InstituteProject ID: P2022-114\/2023 0970 348 000 Research Question\/Objectives: Mantle cell lymphoma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma) | ICES\" \/>\n<meta property=\"og:description\" content=\"Client: HOPE Research Centre, Sunnybrook Research InstituteProject ID: P2022-114\/2023 0970 348 000 Research Question\/Objectives: Mantle cell lymphoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-18T18:10:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\\\/\",\"name\":\"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma) | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2023-05-26T02:28:31+00:00\",\"dateModified\":\"2025-08-18T18:10:57+00:00\",\"description\":\"Client: HOPE Research Centre, Sunnybrook Research InstituteProject ID: P2022-114\\\/2023 0970 348 000 Research Question\\\/Objectives: Mantle cell lymphoma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Private Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma) | ICES","description":"Client: HOPE Research Centre, Sunnybrook Research InstituteProject ID: P2022-114\/2023 0970 348 000 Research Question\/Objectives: Mantle cell lymphoma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/","og_locale":"fr_FR","og_type":"article","og_title":"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma) | ICES","og_description":"Client: HOPE Research Centre, Sunnybrook Research InstituteProject ID: P2022-114\/2023 0970 348 000 Research Question\/Objectives: Mantle cell lymphoma","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-08-18T18:10:57+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/","name":"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma) | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2023-05-26T02:28:31+00:00","dateModified":"2025-08-18T18:10:57+00:00","description":"Client: HOPE Research Centre, Sunnybrook Research InstituteProject ID: P2022-114\/2023 0970 348 000 Research Question\/Objectives: Mantle cell lymphoma","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/costing-and-outcomes-data-for-various-cancer-cohorts-using-administrative-databases-in-ontario-part-iii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Private Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/"},{"@type":"ListItem","position":3,"name":"Costing and outcomes data for various cancer cohorts using administrative databases in Ontario \u2013 Part III (Mantle Cell Lymphoma)"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project\/14644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/private_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=14644"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=14644"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=14644"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=14644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}